Company Filing History:
Years Active: 2012-2025
Title: Ronald Charles Bates – Innovator in Biopharmaceuticals
Introduction
Ronald Charles Bates is a distinguished inventor based in Irvine, California, known for his groundbreaking contributions to the field of biopharmaceuticals. With a remarkable portfolio of 21 patents, he has significantly advanced the way therapeutic proteins are developed and produced, particularly focusing on botulinum neurotoxin and CTLA4-Ig.
Latest Patents
One of Bates' latest patents is titled "Process and system for obtaining botulinum neurotoxin." This invention outlines rapid, animal protein-free, chromatographic processes and systems designed to obtain high potency, high yield botulinum neurotoxin for research, therapeutic, and cosmetic applications. Another notable patent addresses "Compositions and methods for producing a composition," where the invention provides mammalian cells capable of producing recombinant CTLA4-Ig and its variants. It includes compositions comprising CTLA4-Ig, formulations thereof, and methods for mass-producing and purifying this important recombinant protein.
Career Highlights
Throughout his career, Bates has made significant contributions while working with prominent companies in the pharmaceutical industry. Notable among these are Allergan, Inc. and Bristol-Myers Squibb Company, where he has applied his expertise in the development of innovative therapies that benefit countless patients. His dedication to research and development has paved the way for important advancements in medical treatments.
Collaborations
Ronald has collaborated with esteemed professionals in the industry, including Jennifer L. Ton and Hemant A. Patel. Their collective efforts have reinforced the innovative approaches in biopharmaceutical research, leading to superior therapeutic solutions.
Conclusion
In conclusion, Ronald Charles Bates stands out as a significant innovator in the biopharmaceutical sector. His numerous patents and collaborations reflect his commitment to enhancing medical treatment options. As he continues to innovate, the impact of his work is likely to resonate within the industry and beyond, providing new avenues for research and therapeutic advancements.